Riboflavin, FAD, and EGRAC
1 Heap et al. 1999 — Vitamin B Status in CFS (Glutathione Reductase)
Full Citation:: Heap LC, Peters TJ, Wessely S. Vitamin B status in patients with chronic fatigue syndrome. Journal of the Royal Society of Medicine. 1999;92(4):183–185. (Heap, Peters, and Wessely 1999) DOI:: 10.1177/014107689909200405 Key Findings::
- Case-control; $n = 12$ CFS + 18 age/sex-matched controls
- Erythrocyte glutathione reductase (GTR) basal activity reduced in CFS: 6.13 (SD 1.89) vs 7.42 (1.25) U/g Hb ($p < 0.04$)
- Erythrocyte transketolase (TK, thiamine proxy) also reduced: 0.50 vs 0.60 ($p < 0.04$)
- Erythrocyte AST (pyridoxine proxy) most strongly reduced: 2.84 vs 4.61 ($p < 0.001$)
- *Critical limitation:* measured *basal enzyme activity* only, NOT the activation coefficient ratio (EGRAC). Cannot distinguish between reduced enzyme protein mass and functional FAD depletion
- Very small sample ($n = 12$); single centre (King's College London)
- *Certainty: 0.40* — provides directional evidence of reduced functional B vitamin status but the absence of the activation coefficient makes this a near-miss for G23, not a closureRelevance:: The closest existing measurement to EGRAC in ME/CFS — and the most frustrating near-miss. Had Heap et al. computed the activation coefficient (stimulated/basal ratio), G23 might have been partially closed in 1999. The reduced GTR basal activity is consistent with FAD depletion but could also reflect reduced GTR protein expression, oxidative damage to the enzyme, or methodological artefact in a very small sample. The fact that all three B vitamin proxies were reduced suggests a general micronutrient deficiency pattern rather than a riboflavin-specific deficit — though this does not exclude FAD depletion as a contributor.
2 Baraniuk 2025 — CSF Riboflavin and FMN Lower in ME/CFS
Full Citation:: Baraniuk JN. Cerebrospinal fluid metabolomics, lipidomics and serine pathway dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Scientific Reports. 2025;15:7450. (Baraniuk 2025) DOI:: 10.1038/s41598-025-91324-1 Key Findings::
- Case-control CSF metabolomics; nonexercise cohort ($n = 45$ ME/CFS, 20 controls) + postexercise cohort ($n = 15$ ME/CFS, 12 controls)
- Sedentary controls had *higher* CSF riboflavin and FMN than ME/CFS patients
- Riboflavin Metabolism pathway enriched among significantly different CSF metabolites
- Also: 5-MTHF, choline, dimethylglycine higher in controls — broad one-carbon/cofactor deficit
- Exercise provocation: metabolites consumed in ME/CFS but generated in controls — a directional reversal
- *Certainty: 0.55* — peer-reviewed (Scientific Reports), reasonable sample, targeted MS panel; but CSF riboflavin/FMN were secondary findings in a serine pathway paper, not primary endpointsRelevance:: Extends the riboflavin deficit from plasma (Naviaux 2016: FAD reduced) to the central nervous system. If riboflavin and its active form FMN are lower in CSF, this implies that the FAD depletion observed peripherally also affects the brain — where FAD-dependent enzymes (Complex I as FMN-dependent, Complex II, glutathione reductase) are critical for neuronal energy metabolism. Strengthens the case for the riboflavin master-rate-limiter hypothesis (Riboflavin Deficiency as a Multi-Step Master Rate-Limiter) and raises the question of whether oral riboflavin at 400 mg/day achieves adequate CSF penetration.
3 Schoenen et al. 1998 — Riboflavin 400 mg/day for Migraine Prophylaxis (RCT)
Full Citation:: Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomized controlled trial. Neurology. 1998;50(2):466–470. (Schoenen, Jacquy, and Lenaerts 1998) DOI:: 10.1212/WNL.50.2.466 Key Findings::
- RCT; $n = 55$ migraine patients; riboflavin 400 mg/day vs placebo × 3 months
- Riboflavin superior for attack frequency ($p = 0.005$) and headache days ($p = 0.012$)
- 59% responders ($≥$ 50% reduction) vs 15% placebo ($p = 0.002$); NNT = 2.3
- Proposed mechanism: enhanced mitochondrial energy reserve via FAD-dependent Complexes I and II
- Well-tolerated; no significant adverse effects at 400 mg/day
- *Certainty: 0.70* — RCT with clinically meaningful effect size; subsequent meta-analysis (Thompson 2017) and systematic review (2021) broadly confirmRelevance:: The migraine–ME/CFS comorbidity link makes this directly relevant. If riboflavin’s mitochondrial mechanism (FAD→Complex I/II enhancement) explains its migraine efficacy, the same mechanism predicts benefit in ME/CFS where Complex I dysfunction is documented (Heng 2025) and FAD availability is reduced (Naviaux 2016, Baraniuk 2025). The 59% responder rate and NNT of 2.3 would be remarkable if even partially replicated in ME/CFS. The absence of a riboflavin trial in ME/CFS despite this 1998 evidence base is one of the field’s most puzzling omissions.